Search results
Showing 166 to 180 of 314 results for breast cancer
In development Reference number: GID-TA11658 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Discontinued Reference number: GID-TA10531
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued Reference number: GID-TA11178
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Discontinued Reference number: GID-TAG410
Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for HTG722Show all sections
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Discontinued Reference number: GID-TAG391
Discontinued Reference number: GID-TAG432
Awaiting development Reference number: GID-TA11720 Expected publication date: TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development Reference number: GID-TA11022 Expected publication date: TBC
Discontinued Reference number: GID-TA10028
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327